Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
, 24 (2), 171-7

Effect of Coenzyme Q10 Supplementation in Statin-Treated Obese Rats

Affiliations

Effect of Coenzyme Q10 Supplementation in Statin-Treated Obese Rats

Hye-Kyung Choi et al. Biomol Ther (Seoul).

Abstract

Statins, HMG-CoA reductase inhibitors, are known to cause serious muscle injuries (e.g. myopathy, myositis and rhabdomyolysis), and these adverse effects can be rescued by co-administration of coenzyme Q10 (CoQ10) with statins. The goal of the current research is to assess the efficacy of combined treatment of CoQ10 with Atorvastatin for hyperlipidemia induced by high-fat diet in SD rats. 4-week-old Sprague-Dawley male rats were fed normal diet or high-fat diet for 6 weeks. Then, rats were treated with either Statin or Statin with various dosages of CoQ10 (30, 90 or 270 mg/kg/day, p.o.) for another 6 weeks. Compared to Statin onlytreatment, CoQ10 supplementation significantlyreduced creatine kinase and aspartate aminotransferase levels in serum which are markers for myopathy. Moreover, CoQ10 supplementation with Statin further reduced total fat, triglycerides, total cholesterol, and low-density lipoprotein-cholesterol. In contrast, the levels of high-density lipoprotein-cholesterol and CoQ10 were increased in the CoQ10 co-treated group. These results indicate that CoQ10 treatment not only reduces the side effects of Statin, but also has an anti-obesity effect. Therefore an intake of supplementary CoQ10 is helpful for solving problem of obese metabolism, so the multiple prescription of CoQ10 makes us think a possibility that can be solved in being contiguous to the obesity problem, a sort of disease of the obese metabolism.

Keywords: Coenzyme Q10; HMG-CoA reductase; Hyperlipidemia; Myopathy; Statins.

Figures

Fig. 1.
Fig. 1.
Effect of CoQ10 supplementation on adipose tissue weight in Statin-treated obese rats. Data are mean ± S.E. (N=10). *p<0.05, **p<0.01, ***p<0.001 vs. normal diet group, $$$p<0.001 vs. high-fat diet with Statin group. N: normal diet group, NSC270: normal diet with Statin and CoQ10 (270 mg/kg) group, H: high-fat diet group, HS: high-fat diet with Statin group, HC: high-fat diet with CoQ10 (270 mg/kg) group, and HSC30, HSC90, HSC270: high-fat diet with Statin and CoQ10 at various doses (30, 90 or 270 mg/kg) group.
Fig. 2.
Fig. 2.
Histological examination of heart tissues in the high-fat diet rats treated with Statin. Light microscopic finding/myocardium. In longitudinal (A) and transverse section (B), cardiac muscle fibers joined to each other by intercalated discs and having central nuclei and regular striations. 400×.
Fig. 3.
Fig. 3.
Effect of CoQ10 supplementation on serum ALT and AST levels in Statin-treated obese rats. Data are mean ± S.E. (N=10). AST: aspartate aminotransferase, ALT: alanin aminotransferase. **p<0.01, ***p<0.001 vs. normal diet group, $$p<0.01, $$$p<0.001 vs. high-fat diet with Statin group. N: normal diet group, NSC270: normal diet with Statin and CoQ10 (270 mg/kg) group, H: high-fat diet group, HS: high-fat diet with Statin group, HC: high-fat diet with CoQ10 (270 mg/kg) group, and HSC30, HSC90, HSC270: high-fat diet with Statin and CoQ10 at various doses (30, 90 or 270 mg/kg) group.
Fig. 4.
Fig. 4.
Effect of CoQ10 supplementation on serum TG, HDL-C, LDL-C and TC levels in Statin-treated obese rats. Data are mean ± S.E. (N=10). TG: Triglyceride, HDL-C: High-density lipoprotein-cholesterol, LDL-C: Low-density lipoprotein-cholesterol, TC: Total cholesterol. *p<0.05, **p<0.01, ***p<0.001 vs. normal diet group, $p<0.05, $$p<0.01, $$$p<0.001 vs. high-fat diet with Statin group. N: normal diet group, NSC270: normal diet with Statin and CoQ10 (270 mg/kg) group, H: high-fat diet group, HS: high-fat diet with Statin group, HC: high-fat diet with CoQ10 (270 mg/kg) group, and HSC30, HSC90, HSC270: high-fat diet with Statin and CoQ10 at various doses (30, 90 or 270 mg/kg) group.

Similar articles

See all similar articles

Cited by 4 PubMed Central articles

References

    1. Alberts AW, Chen J, Kuron G, Hunt V, Huff J, Hoffman C, Rothrock J, Lopez M, Joshua H, Harris E, Patchett A, Monaghan R, Currie S, Stapley E, Albers-Schonberg G, Hensens O, Hirshfield J, Hoogsteen K, Liesch J, Springer J. Mevinolin: a highly potent competitive inhibitor of hydroxymethylglutaryl-coenzyme A reductase and a cholesterol-lowering agent. Proc Natl Acad Sci USA. 1980;77:3957–3961. doi: 10.1073/pnas.77.7.3957. - DOI - PMC - PubMed
    1. Anand SS. Quantifying effect of statins on low density lipoprotein cholesterol, ischaemic heart disease, and stroke: systematic review and meta-analysis. Law MR, Wald NJ, Rudnicka AR. BMJ 2003; 326: 1407–408. Vasc. Med. 2003;8:289–290. doi: 10.1191/1358863x03vm518xx. - DOI - PubMed
    1. Berthold HK, Naini A, Di Mauro S, Hallikainen M, Gylling H, Krone W, Gouni-Berthold I. Effect of ezetimibe and/or simvastatin on coenzyme Q10 levels in plasma: a randomised trial. Drug Saf. 2006;29:703–712. doi: 10.2165/00002018-200629080-00007. - DOI - PubMed
    1. Bosch X, Poch E, Grau JM. Rhabdomyolysis and acute kidney injury. N Engl J Med. 2009;361:62–72. doi: 10.1056/NEJMra0801327. - DOI - PubMed
    1. Buchholz U, Mouzin E, Dickey R, Moolenaar R, Sass N, Mascola L. Haff disease: from the Baltic Sea to the U.S. shore. Emerg Infect Dis. 2000;6:192–195. doi: 10.3201/eid0602.000215. - DOI - PMC - PubMed

LinkOut - more resources

Feedback